急性髓系白血病的分子靶向治疗
Molecularly targeted therapies for acute myeloid leukemia.
作者信息
Stein Eytan M
机构信息
Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY.
出版信息
Hematology Am Soc Hematol Educ Program. 2015;2015:579-83. doi: 10.1182/asheducation-2015.1.579.
The past 15 years have seen major leaps in our understanding of the molecular genetic mutations that act as drivers of acute myeloid leukemia (AML). Clinical trials of agents against specific mutant proteins, such as FLT3-internal tandem duplications (ITDs) and isocitrate dehydrogenase mutations (IDHs) are ongoing. This review discusses agents in clinical trials that target specific gene mutations and/or epigenetic targets.
在过去的15年里，我们对作为急性髓系白血病（AML）驱动因素的分子基因突变的理解有了重大飞跃。针对特定突变蛋白的药物临床试验正在进行，比如针对FMS样酪氨酸激酶3内部串联重复（FLT3-ITD）和异柠檬酸脱氢酶突变（IDH）的试验。本综述讨论了针对特定基因突变和/或表观遗传靶点的临床试验药物。
Zotero 插件